|
| Role of anti-Siglec-15 in non-small cell lung cancer |
| Received:June 21, 2022 |
| View Full Text View/Add Comment Download reader |
| DOI：10. 3969 / j.issn.1671-7856. 2023. 01. 019 |
| KeyWord:ICIs; Siglec-15; NSCLC |
| Author | Institution |
| 李延康 |
包头市中心医院内蒙古医科大学包头临床医学院心胸外科,内蒙古 包头 |
| 贺钢枫 |
包头市中心医院内蒙古医科大学包头临床医学院心胸外科,内蒙古 包头 |
|
| Hits: 390 |
| Download times: 165 |
| Abstract: |
| As a newly discovered ICI, Siglec-15 is widely expressed in various tumor cell types, and PD-1/ PD-L1 expressions is mutually exclusive. Siglec-15 may be a new therapeutic target for PD-1/ PD-L1 as a treatment option for patients who do not respond to therapy. This review discusses the recent research of the characteristic pathways of Siglec- 15, its involvement in immune regulation mechanisms, and its tumor-related expression. Clinical application of an anti- Siglec-15 antibody was analyzed, and the therapeutic prospect of Siglec-15 for NSCLC treatment is discussed. |
| Close |
|
|
|